In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xeltis AG

Spontaneous natural tissue growth for heart valve replacement

This article was originally published in Start Up

Executive Summary

Rather than relying on an animal or cadaver implant to repair severe congenital heart malformations, Xeltis AG has developed a synthetic and biodegradable replacement pulmonary valve, designed to stimulate and guide the body’s natural healing response. The company’s technology, which has opened up an entirely new therapeutic category called endogenous tissue growth, is designed to provide a single intervention that can last for a lifetime.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT037963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel